BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29707982)

  • 21. [Detection of bladder cancer in voided urine samples].
    Thomas A; Renard I; Waltregny D
    Rev Med Liege; 2009; 64 Spec No():9-14. PubMed ID: 20085009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
    Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
    BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer.
    Schmitz-Dräger BJ; Todenhöfer T; van Rhijn B; Pesch B; Hudson MA; Chandra A; Ingersoll MA; Kassouf W; Palou J; Taylor J; Vlahou A; Behrens T; Critelli R; Grossman HB; Sanchez-Carbayo M; Kamat A
    Urol Oncol; 2014 Oct; 32(7):1061-8. PubMed ID: 24411790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
    Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
    Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
    Chen X; Zhang J; Ruan W; Huang M; Wang C; Wang H; Jiang Z; Wang S; Liu Z; Liu C; Tan W; Yang J; Chen J; Chen Z; Li X; Zhang X; Xu P; Chen L; Xie R; Zhou Q; Xu S; Irwin DL; Fan JB; Huang J; Lin T
    J Clin Invest; 2020 Dec; 130(12):6278-6289. PubMed ID: 32817589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
    Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
    Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
    Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
    BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial.
    Benderska-Söder N; Hovanec J; Pesch B; Goebell PJ; Roghmann F; Noldus J; Rabinovich J; Wichert K; Gleichenhagen J; Käfferlein HU; Köhler CU; Johnen G; Kernig K; Hakenberg O; Jahn D; Todenhöfer T; Stenzl A; Gleissner J; Gerwert K; El-Mashtoly S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2020 Dec; 38(12):886-895. PubMed ID: 32199755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel biomarkers to predict response and prognosis in localized bladder cancer.
    Lucca I; de Martino M; Klatte T; Shariat SF
    Urol Clin North Am; 2015 May; 42(2):225-33, ix. PubMed ID: 25882564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better?
    Keller AK; Jensen JB
    Scand J Urol; 2017 Aug; 51(4):290-292. PubMed ID: 28398114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence.
    Krabbe LM; Woldu SL; Shariat SF; Lotan Y
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1189-1199. PubMed ID: 27696932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.
    Lin SY; Linehan JA; Wilson TG; Hoon DSB
    Eur Urol Focus; 2017 Apr; 3(2-3):265-272. PubMed ID: 28753876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
    Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
    Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 35. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
    Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
    Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
    Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
    Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bladder cancer biomarkers].
    Dobrowolska-Glazar B; Glazar W; Dobrowolski Z; Lipczyński W
    Przegl Lek; 2010; 67(7):479-83. PubMed ID: 21387760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
    Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
    Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.
    Kamat AM; Vlahou A; Taylor JA; Hudson ML; Pesch B; Ingersoll MA; Todenhöfer T; van Rhijn B; Kassouf W; Barton Grossman H; Behrens T; Chandra A; Goebell PJ; Palou J; Sanchez-Carbayo M; Schmitz-Dräger BJ
    Urol Oncol; 2014 Oct; 32(7):1069-77. PubMed ID: 25306288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review.
    Agreda Castañeda F; Raventós Busquets CX; Morote Robles J
    Actas Urol Esp (Engl Ed); 2019 Oct; 43(8):404-413. PubMed ID: 31097210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.